Save the Date – NMD4C Summer School 2024

Save the Date! The NMD4C will be hosting its inaugural basic science research summer school for neuromuscular research trainees over May 27th-28th, 2024 in Montreal, QC. 

The annual NMD4C summer school will serve to provide lecture-based and hands-on training workshops to neuromuscular trainees in cutting-edge wet lab and bioinformatics techniques, while providing an environment for trainees to present their research and network in-person with colleagues and senior investigators from across Canada. This inaugural edition of the summer school will focus on two key themes over the two days: cell culture models derived from patient biopsies, identification of biomarkers, and the use of AAV for rapid genetic manipulations and development of individual based therapeutic approaches (led by Dr Benoit Gentil) and bioinformatics analysis of bulk and single-cell RNA-sequencing data sets (led by Dr Martine Tétreault).  

Supporting preclinical trainees and scientists is a key focus of the network, and we are aiming to make this event as accessible as possible for trainees to attend from across Canada. There will be no registration fee and support will be available for accommodation in Montreal and for travel. 

Our organizing team is hard at work planning the event, and we will provide more details in early January including the event program, information on travel bursaries and accommodation, and how you can apply! 

Save the Date promotion for NMD4C basic research summer school, taking place May 27-28 2024 in Montreal QC.

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.